Polycystic Ovary Syndrome: Dietary Approaches to Counteract Insulin Resistance

Indrani Das¹,²,³

Affiliations
¹Department of Biochemistry, University of Toronto, Ontario, Canada
²Department of Cell and Systems Biology, University of Toronto, Ontario, Canada
³Department of Immunology, University of Toronto, Ontario, Canada

*Please direct correspondence to:
indrani.jui@mail.utoronto.ca

Published online on December 30, 2020

ABSTRACT

Background: Polycystic ovary syndrome (PCOS) is a prevalent hormonal disorder connected to ovulatory infertility and recent research indicates that different diets alter the risk of developing PCOS. Insulin resistance (IR) is one of the key pathologies which classifies PCOS. Understanding the etiology leading to IR in PCOS patients and the disorders associated with IR can allow for a therapeutic measure to be put in place to counteract the etiology and even reduce the risk of developing the disorder.

Objective: The objective of this review is to identify the key factors that lead to IR so that diet and other lifestyle aspects can be used to counteract PCOS Symptoms.

Design: A total of 679 studies were taken into consideration for this review, however, I performed a literature review of 75 primary papers. Data and findings from these studies were used to gain a better understanding of the dietary etiology of IR in PCOS, and this information can be used to describe a specific diet to counteract its etiology.

Results: Many symptoms and disorders in the biological pathway of PCOS is associated with IR. Clinical studies have established that an increase in carbohydrates, low-density lipoproteins, and triglycerides is associated with IR in PCOS patients. Similar studies have found that a decrease in dietary proteins (especially branched chain amino acid intake), lactate, phosphatidylcholine, high-density lipoproteins, and long-chain fatty acids are also associated with PCOS patients. The drug metformin has also been associated with ameliorating many of the negative impacts imposed by IR in PCOS patients. Addressing these factors and changing diet and lifestyle (such as increased exercise) can help reduce the IR-related effects in PCOS patients.

Keywords: Polycystic Ovary Syndrome, Insulin Resistance, Diet, Therapy
INTRODUCTION

Polycystic ovary syndrome (PCOS) is a prevalent hormonal disorder connected to ovulatory infertility and metabolic disorders. This disorder primarily affects women of reproductive age. In females, this disorder is associated with endocrinial and metabolic symptoms, and in males, only metabolic symptoms are observed. PCOS is multi-faceted and therefore the pathogenesis is multigenetic. One of the primary pathologies leading to PCOS is insulin resistance (IR). IR can further lead to other metabolic and endocrine complications. The prevalence of PCOS is unclear; however, estimates in subpopulations have revealed a consensus prevalence rate is believed to be about 3-10% for most populations. However, this number may be higher because some affected patients have not been diagnosed due to social and economical factors such as insufficient medical care. In Canada, PCOS is one of the most common endocrine disorders with a prevalence rate of 4-12%.

According to the criteria established by the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM), PCOS can only be diagnosed when multiple symptoms are manifested and if other disorders are first excluded. PCOS is characterized by high blood levels of androgens, increased luteinizing hormone secretion, hyperinsulinemia and IR, hormone imbalance, and genetic inheritance.

This review will focus on the etiology behind IR and hyperinsulinemia and its association to cascading symptoms of PCOS. Due to the heterogeneity of the disorder, other factors such as obesity and hyperandrogenism will be discussed as well. Dietary and lifestyle changes will be analyzed to develop the best interventions to counteract IR and thus reduce the symptoms of PCOS.

METHODS

Search Strategy

PubMed, EMBASE, and the University of Toronto Libraries system were searched using key words “lactate+pcos”, “long-chain fatty acids+pcos”, “triglycerides+pcos”, “low-density lipoproteins+pcos”, “high-density lipoproteins+pcos”, “glucose+pcos”, “phosphatidylcholine+pcos”, and “amino acids+pcos”. The reference list of the studies found were further reviewed to find related publications. Randomized controlled trials and longitudinal studies until April 2020 were considered. The quality of the pooled evidence was assessed using the GRADE (grading of recommendations assessment, development, and evaluation) approach. In total, 679 possible studies were identified.

Study Selection

Inclusion Criteria

Prospective studies investigating the association between PCOS and diet (where the diet can both increase or decrease the risk of PCOS) were included. For a systematic review to be conducted, studies which reported an odds ratio with 95% confidence limits were selected.

Exclusion Criteria

Studies conducted for PCOS are often disadvantaged by small sample sizes, selection biases, and lack of comparability between studies. Studies were excluded if they had sample sizes less than 100 participants, if the results of a study with selection bias could not be replicated by other studies, or if they did not strictly identify participants based on either the Rotterdam Criteria, National Institutes of Health Criteria, or a diagnosis by a healthcare professional.

Data Extraction

Data extracted from the studies included the first author’s last names, publication date, research location, sample size, age range of participants, recruitment procedure, method of PCOS diagnosis, follow-up period, consideration of variables, and type of statistical analysis.

Figure 1 Guidelines for the diagnosis of PCOS and the associated symptoms

DETAILED ANALYSIS OF DIETARY CONSIDERATIONS

Protein Intake

The body’s digestive system breaks down proteins into amino acids (AAs) and the composition of the AAs can alleviate or aggravate symptoms in PCOS patients. Zhang et al. (2014) elucidated the interaction between AA metabolic disturbances (increased and decreased) and an increased risk of IR associated with PCOS. Furthermore, this disruption in AA composition and metabolic profile may be the reason for poor pregnancy outcomes and increased miscarriage risk...
in PCOS patients\textsuperscript{9}. Specifically, branched-chain AAs (BCAAs) and an increase in a few essential AAs are found to have a strong association with the alleviation of IR in PCOS patients. Extensive evidence of studies not associated with PCOS further illustrates that increased BCAAs and essential AAs are associated with obesity, IR, and type 2 diabetes, all of which are symptoms of PCOS\textsuperscript{10,11}.

Many studies have drawn an association between increased levels of lysine, leucine, serine, threonine, valine, homocysteine, and glutamic acid in PCOS patients compared to non-PCOS patients\textsuperscript{9,12–15}. A decrease of plasma BCAAs compared to other aromatic AAs was directly correlated with the development of PCOS\textsuperscript{14}. Among PCOS patients, there were discrepancies between pregnant and non-pregnant patients; pregnant patients have a higher level of aspartic acid and serine, while non-pregnant pregnant patients; pregnant patients have a higher level of threonine, valine, homocysteine, and glutamic acid in PCOS patients compared to non-PCOS patients\textsuperscript{9}. Among these statistically significant AAs, the findings about valine and glutamic acid are most reliably associated with PCOS since they were independently discovered in many studies. Increased levels of valine and leucine and decreased levels of glycine in the plasma of PCOS patients could also contribute to insulin sensitivity\textsuperscript{14}.

Evidence collected from these studies indicate that a diet with increased BCAAs and glutamic acid are found in meat, eggs, dairy products, nuts, and legumes\textsuperscript{16,17}. This diet decreases the risk of developing PCOS and IR related symptoms\textsuperscript{16,17}. The work by Rousseau et al. found that an increase in dietary BCAAs can be correlated with an increase in plasma BCAAs\textsuperscript{16}.

Carbohydrate Intake

Carbohydrates, both simple and complex, are broken down into monosaccharides including glucose and other monosaccharides. The glycemic index is a ranking method to determine how quickly blood sugar levels are increased after eating\textsuperscript{18}. A high glycemic diet is not only associated with IR, but also higher androgen levels\textsuperscript{19}. This diet also increases susceptibility to inflammation and oxidative stress which leads to cardiovascular disorders (CD) and estrogen-dependent cancers\textsuperscript{19}.

A reduced caloric diet can ameliorate symptoms of PCOS by reducing body weight, fat mass, and serum cholesterol\textsuperscript{20}. The associated risk of carbohydrates with IR can be attributed to a higher insulin clearance as found by Stassek et al\textsuperscript{21}. A reduced carbohydrate intake is associated with overall reduced insulin exposure, which may be the reason for the selective depletion of adipose tissue and preservation of lean body mass\textsuperscript{22}. The study by Cutler et al. found that carbohydrates lead to increased IR related symptoms such as obesity, which contradicted the misconception that obesity in PCOS patients is due to overeating or inactivity\textsuperscript{23}. Reduction in glycemic index for a prolonged period of time inhibits inflammatory factor synthesis\textsuperscript{24}. Additionally, increasing dietary fiber and magnesium and lowering carbohydrate intakes may reduce IR\textsuperscript{23,25}.

Protein vs. Carbohydrates

Kasim-Karakas et al. elucidated that a diet of proteins can reduce the risk for developing PCOS, whereas a diet of carbohydrates can aggravate symptoms such as IR and hyperinsulinemia due to higher glucose levels\textsuperscript{26}. This study further showed that the intake of protein rather than carbohydrates can cause the suppression of the hormone ghrelin (increases body weight and fat mass) due to ghrelin’s sensitivity to insulin (higher in a protein diet)\textsuperscript{26}.

Fat Intake

Fats are a type of lipids made up of fatty acids and triglycerides\textsuperscript{27}. Fatty acid composition can be used as biomarkers for several pathologies such as PCOS\textsuperscript{28}.

Long-Chain Fatty Acids (LCFA)

LCFA are fatty acids have aliphatic tails containing 13 to 21 carbons\textsuperscript{28}. One of the more common LCFA found to be beneficial in alleviating risk of developing PCOS is Omega-3 polyunsaturated fatty acids (n-3 PUFAs)\textsuperscript{29}. In this case, n-3 PUFAs were found to be one of the few LCFA to have a substantial impact on decreasing the risk of developing PCOS. N-3 PUFAs were found to be beneficial for PCOS patients because it is associated with anti-obesity effects, glycemic and hormonal homeostasis, anti-inflammatory effects, and an enhancement of endothelial function\textsuperscript{30}. Increased LCFA intake can lead to significant metabolic and endocrine effects such as an increase in glucose and decrease in plasma free fatty acids\textsuperscript{31}. PUFAs modulate hormonal and lipid profiles and improve androgenic profiles\textsuperscript{32}. Furthermore, Rafraf et al. found that n-3 PUFAs improved oxidative stress in women with PCOS\textsuperscript{33,34}. A discrepancy in the findings is that Li et al. found that obese PCOS patients are associated with lower levels of PUFAs and higher levels of saturated LCFA as compared to the lean controls\textsuperscript{35}. Future studies needed to understand the inverse correlation between BMI and PUFAs.

The ingestion of LCFA promotes IR and a proinflammatory state are dietary consumption of trans fatty acids. Further research needs to be conducted to understand the biochemical pathway associated with this finding\textsuperscript{36}.

N-3 PUFA may be a treatment for PCOS, more specifically, the symptoms of IR, high LDL, and triglycerides\textsuperscript{37}. Ingestion of PUFA may directly influence insulin secretion and resistance and indirectly affect plasma AA levels\textsuperscript{38}. Increased fatty acids leads to a lower IR\textsuperscript{39}. N-3 PUFA supplements have been found in the study by Salek et al. to alleviate symptoms of PCOS, however a clear association has not been made between the symptoms and dietary impacts\textsuperscript{30}.
**Triglycerides**

Triglyceride levels have been found to be higher in the blood of PCOS patients. If there is a high amount of triglycerides compared to a low amount of high density lipoproteins (HDL), the prevalence of IR is higher. Contradicting evidence shows that when associated with obese and diabetic PCOS patients, PCOS is mainly characterized by hypertriglycerideremia. Hypertriglycerideremia can lead to a higher risk of visceral obesity and non-alcoholic fatty liver disease. A high fat intake right before fasting time (sleeping through the night) may cause reduced fat energy consumption due to the diminished ability for lipid oxidation, which may lead to hypertriglyceridermia in PCOS patients.

An increased plasma triglyceride levels in obese adolescent patients provides evidence of early subclinical cardiovascular disorder (CD) risk due to impaired insulin metabolism and hyperandrogenemia. This trend can be seen in patients older than 30 years of age irrespective of body mass index as there is prevalent hypertension and increased carotid intima media thickness of common carotid arteries. Rashidi et al. found that in obese women, the triglyceride level is higher whereas cholesterol is higher in lean women. High triglycerides levels are associated with hyperandrogenism in PCOS patients. Huddleston et al. found that increasing age among reproductive-aged women with PCOS leads to a steeper increase in CD associated with IR including triglycerides even though they additionally observed a decline in biochemical hyperandrogenaemia over time.

**Transport Systems of Fats**

Improper transportation of fats can lead to dyslipidemia, which is an accumulation of fats in the blood. Patients with PCOS have dyslipidemia which is caused by an interplay between genetics, adiposity, and environmental factors.

**High-Density Lipoproteins (HDL)**

PCOS patients have an atherogenic lipid plasma profile with decreased levels of HDL as a result of their insulin resistant state. The association of PCOS patients with CD can be attributed to the lower levels of HDL and higher levels of LDL. Rajkhowa et al. found that this association with lower HDL levels and PCOS is more evident in obese patients compared to lean patients. Obese female patients with PCOS have a distinct metabolic signature during fasting and hyperinsulinemia. Specifically, the level of triglycerides has a reciprocal relationship with HDL-C and the ratio of triglycerides and HDL-C is associated with IR for PCOS patients. A reduction in HDL reduces antioxidant and anti-inflammatory pathways which lead to high levels of ROS and inflammatory factors.

**Low-Density Lipoproteins (LDL)**

PCOS patients have high LDL levels including an increase in atherogenic small dense LDL. This increase in plasma LDL can be attributed to IR. Increased very low-density lipoprotein production and reduced clearance of lipoprotein lipase due to IR leads to hypertriacylglycerolemia through the reverse cholesterol transport pathway. This results in low HDL and high LDL levels. Dyslipidemia caused by IR and unfavourable proatherogenic lipoprotein ratios is found in PCOS female patients and not in controls. This may result in an increased risk of premature atherosclerosis. An increase of small dense LDL is associated with an increased risk of developing CD by 3- to 7- fold. This quantitative risk factor does not include the risk associated with increased LDL cholesterol concentration. Elevated serum lipoproteins may also contribute to the development of atherosclerosis and increased CD. Increased levels of LDL are also related with abnormal ovarian function due to its influence on the irregular development of follicles. Abnormalities in the early stages of folliculogenesis are one of the main causes of anovulation in PCOS.

**Figure 2** Summary of factors leading to and disorders caused by IR. The arrows indicate causal claims.

**Ameliorating the Atherogenic Lipid Profile**

Metabolic complications due to proatherogenic lipid profile changes should be taken into consideration when considering therapeutic strategies for PCOS patients. Potential therapies associated with decreasing the risk of developing CD in association with PCOS patients and hyperinsulinemia is the use of the drug metformin. Metformin can be considered as a prophylactic therapy. Metformin decreases oxidized lipids in the blood which improves oxidative stress.

Along with changes in diet, it has been found that moderate-intensity exercise can improve components of the lipoprotein profile of PCOS patients so that there is less risk of developing the aforementioned disorders. Dokras et al. has found that the use of oral contraceptive pills combined with lifestyle changes as stated above can lead to improved HDL-C function.
**Phosphatidylcholine**

Phosphatidylcholine is a major class of human plasma phospholipids and is composed of highly diverse fatty acids67. It is important for follicular growth and may influence the metabolism of glucose and lipids67. PCOS patients are reported to have abnormally higher levels of plasma phosphatidylcholine35,68. This lipid may be useful as a biomarker for the plasma carbohydrate to fat ratio, especially during the menstrual cycle luteal phase34,41,69–71. Hypertriglyceridemia as previously discussed can lead to an increase in inflammatory mediators such as the of the prostaglandin E2 pathway and o xo-leukotrienes in PCOS patients45. Phosphatidylcholine may be important for insulin production which then impacts other parts of the follicular growth pathways72. The main sources of phosphatidylcholine from dietary intake are eggs, meat, and supplementation73.

**Lactate**

When the body does not have enough oxygen to break down the carbohydrates into glucose, the substance lactate is produced in order to supply ATP74. Lactate production is associated with the growth and maturation of ovarian follicles60,75,76. Irregular lactate production associated with PCOS may induce dyslipidemia, low-grade inflammation, and AA metabolism in follicular fluids77. Insulin is hypothesized to stimulate lactate formation by granulosa-lutein cells which are impaired in insulin resistant PCOS patients78. Gunalan et al. hypothesizes that dietary supplementation with lactate may help alleviate symptoms of PCOS79. The drug metformin was found to also stimulate lactate production by enhancing the function of suboptimal insulin concentrations. IR, hyperinsulinemia, and obesity lead to insufficient lactate production which leads to abnormal menstrual cycles, folliculogenesis, and fertility78,80. Positive changes in lifestyle and diet may lead to spontaneous ovulation and improve fertility rate in the majority of patients80.

**CONCLUSION**

PCOS is a multifaceted disorder and identifying the specific risks of developing disorders associated with PCOS can aid in selecting appropriate interventions to improve the health of patients. Clinical studies have found strong associations between supplementation of various compounds and improving symptoms of PCOS; however, further studies need to take place to find more reliable evidence of dietary intake of compounds and their impact on PCOS. Overall, an increase in protein (specifically BCAA) intake instead of carbohydrates, increase in n-3 PUFA, phosphatidylcholine, lactate, and the use of the drug metformin combined with exercise is deemed to be appropriate lifestyle changes that will counteract IR in PCOS and thereby reduce the impact of this disorder.

**COMPETING INTERESTS**

No competing interests declared.

Received: May 14, 2020
Accepted: September 25, 2020
Published online: December 30, 2020

**REFERENCES**

1. Bellver, J. et al. Polycystic ovary syndrome throughout a woman’s life. J. Assist. Reprod. Genet. 35, 25–39 (2018).
2. Dušková, M., Hill, M., Va, M., Šámalíková, P. & Stárka, L. What May Be the Markers of the Male Equivalent of Polycystic Ovary Syndrome? 53, 8 (2004).
3. Pasquali, R. & Gambineri, A. Polycystic Ovary Syndrome. Ann. N. Y. Acad. Sci. 1092, 158–174 (2006).
4. Wolf, W. M., Watnick, R. A., Kinkade, O. N. & Olfert, M. D. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. Int. J. Environ. Res. Public. Health 15, (2018).
5. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. - PubMed - NCBI. https://www.ncbi.nlm.nih.gov/pubmed/14711538.
6. Diamanti-Kandarakis, E., Papavassiliou, A. G., Kandarakis, S. A. & Chrousos, G. P. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol. Metab. 18, 280–285 (2007).
7. Couto Alves, A. et al. Metabolic profiling of polycystic ovary syndrome reveals interactions with abdominal obesity. Int. J. Obes. 41, 1331–1340 (2017).
8. Berg, J. M., Tymoczko, J. L. & Stryer, L. Proteins Are Degraded to Amino Acids. Biochem. 5th Ed. (2002).
9. Zhang, C. et al. Metabolic heterogeneity of follicular amino acids in polycystic ovary syndrome is affected by obesity and related to pregnancy outcome. BMC Pregnancy Childbirth 14, 11 (2014).
10. Batch, B. C. et al. Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. Metabolism 62, 961–969 (2013).
11. Newgard, C. B. Interplay between Lipids and Branched-Chain Amino Acids in Development of Insulin Resistance. Cell Metab. 15, 606–614 (2012).
12. Chang, A. et al. Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome. Metabolism 71, (2017).
13. Cree-Green, M. et al. Amino Acid and Fatty Acid Metabolomic Profile during Fasting and Hyperinsulinemia in girls with Polycystic Ovarian Syndrome. Am. J. Physiol.-Endocrinol. Metab. 316, (2019).
14. Zhao, Y. et al. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med. 10, 153 (2012).
15. Saadeh, N. et al. Serum homocysteine is associated with polycystic ovarian syndrome in Jordan. Biomed. Rep. 9, 439–445 (2018).
16. Rousseau, M. et al. Associations Between Dietary Protein Sources, Plasma BCAA and Short-Chain Acylcarnitine Levels in Adults. Nutrients 11, (2019).
Polycystic Ovary Syndrome: Dietary Approaches to Counteract Insulin Resistance

17. Stamler, J. et al. Glutamic Acid – the Main Dietary Amino Acid – and Blood Pressure: The INTERMAP Study. Circulation 120, 221–228 (2009).
18. Holesh, J. E. & Martin, A. Physiology, Carbohydrates. in StatPearls Publishing (2020).
19. Szczuko, M. et al. High glycemic index diet in PCOS patients. The analysis of IGF I and TNF-a pathways in metabolic disorders. Med. Hypotheses 96, 42–47 (2016).
20. Kasim-Karakas, S. E., Almario, R. U. & Cunningham, W. Effects of protein versus simple sugar intake on weight loss in polycystic ovary syndrome (according to the National Institutes of Health criteria). Fertil. Steril. 92, 262–270 (2009).
21. Stassek, J. et al. C-Peptide, Baseline and Postprandial Insulin Resistance after a Carbohydrate-Rich Test Meal – Evidence for an Increased Insulin Clearance in PCOS Patients? Geburtshilfe Frauenheilkd. 77, 59–65 (2017).
22. Goss, A. M. et al. Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOS. Metabolism 63, 1257–1264 (2014).
23. Cutler, D. A., Pride, S. M. & Cheung, A. P. Low intakes of dietary fiber and magnesium are associated with insulin resistance and hyperandrogenism in polycystic ovary syndrome: A cohort study. Food Sci. Nutr. 7, 1426–1437 (2019).
24. Szczuko, M., Drozd, A., Maciejewska, D., Zapalowska-Chwyć, M. & Stachowska, E. Decrease in the level of nervous acid and increased gamma linolenic acid in the plasma of women with polycystic ovary syndrome after a three-month low-glycaemic index and calorific reduction diet. Open Life Sci. 14, 224–236 (2019).
25. Eslamian, G., Baghestani, A.-R., Eghtesad, S. & Hekmatdoost, A. Dietary carbohydrate composition is associated with polycystic ovary syndrome: a case–control study. J. Hum. Nutr. Diet. 30, 90–97 (2017).
26. Kasim-Karakas, S. E., Cunningham, W. M. & Tsiodrik, A. Relation of nutrients and hormones in polycystic ovary syndrome. Am. J. Clin. Nutr. 85, 688–694 (2007).
27. Health, N. R. C. (US) C. on D. and. Fats and Other Lipids. Relation and caloric reduction diet. Open Life Sci. 14, 224–236 (2019).
28. Kim, J. J. & Choi, Y. M. Dyslipidemia in women with polycystic ovary syndrome. Obstet. Gynecol. Sci. 56, 137–142 (2013).
29. Vargas, M. L., Almario, R. U., Buchan, W., Kim, K. & Karakas, S. E. Metabolic and Endocrine Effects of Long Chain vs. Essential Omega-3 Polysaturated Fatty Acids in Polycystic Ovary Syndrome. Metabolism. 60, 1711–1718 (2011).
30. Salek, M., Clark, C. C. T., Taghizadeh, M. & Jafarnejad, S. N-3 fatty acids as preventive and therapeutic agents in attenuating PCOS complications. EXCLI J. 18, 558–575 (2019).
31. Kasim-Karakas, S. E. et al. Metabolic and Endocrine Effects of a Polysaturated Fatty Acid-Rich Diet in Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 89, 615–620 (2004).
32. Phelan, N. et al. Lipoprotein Subclass Patterns in Women with Polycystic Ovary Syndrome (PCOS) Compared with Equally Insulin-Resistant Women without PCOS. J. Clin. Endocrinol. Metab. 95, 3933–3939 (2010).
33. Rafraf, M. & Mohamadi, E. PP104-MON: Omega-3 Fatty Acids Improves Oxidative Stress in Women with Polycystic Ovary Syndrome. Clin. Nutr. 33, S168 (2014).
34. Cordeiro, F. B. et al. Follicular fluid lipid fingerprinting from women with PCOS and hyper response during IVF treatment. J. Assist. Reprod. Genet. 32, 45–54 (2015).
35. Li, S. et al. Discovery of Novel Lipid Profiles in PCOS: Do Insulin and Androgen Oppositely Regulate Bioactive Lipid Production? J. Clin. Endocrinol. Metab. 102, jc.2016-2692 (2016).
36. Ożegowska, K., Bogacz, A., Bartkowiak-Wieczorek, J., Seremak-Mroziakiewicz, A. & Pawelczyk, L. Is there an association between the development of metabolic syndrome in PCOS patients and the C677T MTHFR gene polymorphism? Ginekol. Pol. 87, 246–253 (2016).
37. Yang, K., Zeng, L., Bao, T. & Ge, J. Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis. Reprod. Biol. Endocrinol. 16, 27 (2018).
38. Kasikas, S. E., Perroud, B., Kind, T., Palazoglu, M. & Fiehn, O. Changes in plasma metabolites and glucose homeostasis during omega-3 polyunsaturated fatty acid supplementation in women with polycystic ovary syndrome. BBA Clin. 5, 179–185 (2016).
39. Ek, I. et al. A Unique Defect in the Regulation of Visceral Fat Cell Lipolysis in the Polycystic Ovary Syndrome as an Early Link to Insulin Resistance. Diabetes 51, 484–492 (2002).
40. Amini, L., Sadeghi, M., Oskouie, F., Kamali, K. & Maleki, H. Lipid Profile in Women with Polycystic Ovary Syndrome. Crescent J. Med. Biol. Sci. 1, 147–150 (2014).
41. Song, D. K., Lee, H., Sung, Y.-A. & Oh, J.-Y. Triglycerides to High-Density Lipoprotein Cholesterol Ratio Can Predict Impaired Glucose Tolerance in Young Women with Polycystic Ovary Syndrome. Yonsei Med. J. 57, 1404–1411 (2016).
42. Sreenivasulu, K., V.S., K. & Rajendra Prasad, N. (PDF) Association of triglycerides/high density lipoprotein cholesterol ratio with insulin resistance in polycystic ovary syndrome. ResearchGate https://www.researchgate.net/publication/329215774_Association_of_triglycerideshigh_density_lipoprotein_cholesterol_ratio_with_insulin_resistance_in_polycystic_ovary_syndrome.
43. Anifa, C. A., Lobota, M., Esimo, M. & Pozzilli, P. Metabolic Disorders Associated with Biological Insulin Resistance in Congolese Woman with Polycystic Ovary Syndrome (PCOS). Testes Ovaries - Funct. Clin. Differ. Similarities (2017) doi:10.5772/ 169182.
44. Brouzeng, C. et al. Triglycerides as a Metabolic Target in Afrocaribbean Infertile Women with Polycystic Ovary Syndrome. Metab. Syndr. Relat. Disord. 17, 500–504 (2019).
45. Monica, C. L. et al. Lipidomics biomarkers in women with polycystic ovary syndrome (PCOS) using ultra-high performance liquid chromatography–quadrupole time of flight electrospray in a positive ionization mode mass spectrometry. Scand. J. Clin. Lab. Invest. 79, 437–442 (2019).
46. Vine, D. F., Wang, Y., Jetha, M. M., Ball, G. D. & Proctor, S. D. Impaired ApoB-Lipoprotein and Triglyceride Metabolism in Obese Adolescents With Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 102, 970–982 (2017).
47. Macut, D. et al. Predictors of Subclinical Cardiovascular Disease in Women with Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and Arterial Blood Pressure: The INTERMAP Study. Circulation 120, 221–228 (2009).
48. Serum lipid profile and insulin resistance in women with polycystic ovary syndrome (PCOS). J. Diabetes Metab. Disord. Control Volume 5, (2018).
49. Hestiantoro, A. et al. Triglycerides, independent of Ferriman Gallwey Score, is a main determinant of free testosterone index in PCOS. F1000Research 8, (2019).

50. Huddleston, H. G. et al. Women with polycystic ovary syndrome demonstrate worsening markers of cardiovascular risk over the short-term despite declining hyperandrogenaemia: Results of a longitudinal study with community controls. Clin. Endocrinol. (Oxf.) 87, 775–782 (2017).

51. Essah, P. A., Nestler, J. E. & Carmina, E. Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome. J. Endocrinol. Invest. 31, 35–41 (2008).

52. Moran, L. J., Mundra, P. A., Teede, H. J. & Meikle, P. J. The association of the lipidomic profile with features of polycystic ovary syndrome. J. Mol. Endocrinol. 59, 93–104 (2017).

53. Gourgari, E. et al. Lipoprotein Particles in Adolescents and Young Women With PCOS Provide Insights Into Their Cardiovascular Risk. J. Clin. Endocrinol. Metab. 100, 4291–4298 (2015).

54. Mallick, S., Khatun, S. & Islam, S. Dyslipidemia in Women with Polycystic Ovary Syndrome: Comparison between Obese Cases and Obese Controls in a Government Hospital in West Bengal. 6, 5 (2018).

55. Rajkhowa, M. et al. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82, 3389–3394 (1997).

56. Liu, Q., Xie, Y., Qu, L., Zhang, M. & Mo, Z. Dyslipidemia involvement in the development of polycystic ovarian syndrome. Taiwan. J. Obstet. Gynecol. 58, 447–453 (2019).

57. Macut, D. et al. Lipid and lipoprotein profile in women with polycystic ovary syndromeThis article is one of a selection of papers published in the special issue Bridging the Gap: Where Progress in Cardiovascular and Neurophysiologic Research Meet. Can. J. Physiol. Pharmacol. 86, 199–204 (2008).

58. Pirwany, I. R., Fleming, R., Greer, I. A., Packard, C. J. & Sattar, N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin. Endocrinol. (Oxf.) 54, 447–453 (2001).

59. R., S., BV, R. & KS, N. Serum lipoprotein (a) and lipid profile in women with polycystic ovary syndrome and Obese Controls in a Government Hospital in West Bengal. 6, 5 (2018).

60. Rajkhowa, M. et al. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82, 3389–3394 (1997).

61. Liu, Q., Xie, Y., Qu, L., Zhang, M. & Mo, Z. Dyslipidemia involvement in the development of polycystic ovarian syndrome. Taiwan. J. Obstet. Gynecol. 58, 447–453 (2019).

62. Macut, D. et al. Lipid and lipoprotein profile in women with polycystic ovary syndromeThis article is one of a selection of papers published in the special issue Bridging the Gap: Where Progress in Cardiovascular and Neurophysiologic Research Meet. Can. J. Physiol. Pharmacol. 86, 199–204 (2008).

63. Pirwany, I. R., Fleming, R., Greer, I. A., Packard, C. J. & Sattar, N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin. Endocrinol. (Oxf.) 54, 447–453 (2001).

64. Brown, A. J. et al. Effects of Exercise on Lipoprotein Particles in Women with Polycystic Ovary Syndrome. Med. Sci. Sports Exerc. 41, 497–504 (2009).

65. Iath, R. Insulin resistance and lipid profile in polycystic ovary syndrome. Asian J. Biomed. Pharm. Sci. 05, 30–35 (2015).

66. Dokras, A. et al. Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 86, 739–746 (2017).

67. Inoue, M. et al. Effects of the dietary carbohydrate–fat ratio on plasma phosphatidylcholine profiles in human and mouse. J. Nutr. Biochem. 50, 83–94 (2017).

68. Huang, J., Liu, L., Chen, C. & Gao, Y. PCOS without hyperandrogenism is associated with higher plasma Trimethylamine N-oxide levels. BMC Endocr. Disord. 20, 3 (2020).

69. Haoula, Z. et al. Lipidomic analysis of plasma samples from women with polycystic ovary syndrome. Metabolomics 11, 657–666 (2015).

70. Jiang, Y. et al. Ceramide subclasses identified as novel lipid biomarker elevated in women with polycystic ovary syndrome: a pilot study employing shotgun lipidomics. Gynecol. Endocrinol. 0, 1–5 (2019).

71. Jové, M. et al. Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome. Oncotarget 9, 4522–4536 (2017).

72. Clore, J. N. et al. Changes in phosphatidylcholine fatty acid composition are associated with altered skeletal muscle insulin responsiveness in normal man. Metab.-Clin. Exp. 49, 232–238 (2000).

73. Zheng, Y. et al. Dietary phosphatidylcholine and risk of all-cause and cardiovascular-specific mortality among US women and men. Am. J. Clin. Nutr. 104, 173–180 (2016).

74. Jensen, J., Rustad, P. I., Kolnes, A. J. & Lai, Y.-C. The Role of Skeletal Muscle Glycogen Breakdown for Regulation of Insulin Sensitivity by Exercise. Front. Physiol. 2, (2011).

75. Boland, N. I., Humpherson, P. G., Leese, H. J. & Gosden, R. G. Pattern of Lactate Production and Steroidogenesis during Growth and Maturation of Mouse Ovarian Follicles in Vitro. Biol. Reprod. 48, 798–806 (1993).

76. Harris, S. E., Maruthini, D., Tang, T., Balen, A. H. & Picton, H. M. Metabolism and karyotype analysis of oocytes from patients with polycystic ovary syndrome. Hum. Reprod. 25, 2305–2315 (2010).

77. Zhang, Y., Liu, L., Yin, T.-L., Yang, J. & Xiong, C.-L. Follicular metabolic changes and effects on oocyte quality in polycystic ovary syndrome patients. Oncotarget 8, 80472–80480 (2017).

78. Fedorcsak, P., Storeng, R., Dale, P. O., Tanbo, T. & Åbyholm, T. Impaired insulin action on granulosa-lutein cells in women with polycystic ovary syndrome and insulin resistance. Gynecol. Endocrinol. 14, 327–336 (2000).

79. Günelan, E., Yaba, A. & Yılmaz, B. The effect of nutrient supplementation in the management of polycystic ovary syndrome-associated metabolic dysfunctions: A critical review. J. Turk. Ger. Nutr. Assoc. 19, 220–232 (2018).

80. Pasquali, R. & Gambineri, A. Role of changes in dietary habits in polycystic ovary syndrome. Reprod. Biomed. Online 8, 431–439 (2004).